Get the Stockscreener App
1.40
8.50%
-0.13
After Hours:
1.35
-0.05
-3.57%
Quince Therapeutics Inc stock is traded at $1.40, with a volume of 378.73K.
It is down -8.50% in the last 24 hours and up +77.55% over the past month.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing innovative precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics.
See More
Previous Close:
$1.53
Open:
$1.51
24h Volume:
378.73K
Relative Volume:
0.72
Market Cap:
$64.49M
Revenue:
-
Net Income/Loss:
$-31.39M
P/E Ratio:
-1.6867
EPS:
-0.83
Net Cash Flow:
$-18.45M
1W Performance:
+18.64%
1M Performance:
+77.55%
6M Performance:
+42.12%
1Y Performance:
+48.29%
1-Day Range:
$1.40
$1.545
1-Week Range:
$1.228
$1.79
52-Week Range:
$0.5116
$1.79
Quince Therapeutics Inc Stock (QNCX) Company Profile
Name
Quince Therapeutics Inc
Sector
Industry
Phone
415-910-5717
Address
611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO
Quince Therapeutics Inc Stock (QNCX) Latest News
Quince Therapeutics (NASDAQ:QNCX) Raised to “Strong-Buy” at RODMAN&RENSHAW - Defense World
Quince Therapeutics (NASDAQ:QNCX) Upgraded to Strong-Buy at RODMAN&RENSHAW - MarketBeat
Rodman & Renshaw sets stock target, buy rating on Quince Therapeutics - Investing.com
Rodman & Renshaw Initiates Coverage of Quince Therapeutics (QNCX) with Buy Recommendation - MSN
Quince Therapeutics shares rated Buy at EF Hutton, optimistic about EryDex's potential - Investing.com Canada
EF Hutton Initiates Coverage of Quince Therapeutics (QNCX) with Buy Recommendation - MSN
Quince Therapeutics to Participate at Upcoming Investor Conferences - Business Wire
Quince Therapeutics (NASDAQ:QNCX) Shares Down 5.1% - Defense World
Finalist, Public Company, Medium: Christopher J. Senner, Exelixis Inc. - The Business Journals
Ataxia Telangiectasia Market Growth to Accelerate in Forecast - openPR
Quince Therapeutics, Inc. (NASDAQ:QNCX) CEO Dirk Thye Purchases 77,500 Shares - Defense World
Quince Therapeutics CEO acquires $107k in company stock - Investing.com
Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
The Potential Rise in the Price of Quince Therapeutics Inc (QNCX) following insiders activity - Knox Daily
Healthy Upside Potential: Quince Therapeutics Inc (QNCX) - SETE News
Have you been able to find a good deal on Quince Therapeutics Inc’s shares? - US Post News
Charles S. Ryan Purchases 48,387 Shares of Quince Therapeutics, Inc. (NASDAQ:QNCX) Stock - Defense World
Brendan Hannah Buys 30,845 Shares of Quince Therapeutics, Inc. (NASDAQ:QNCX) Stock - Defense World
Quince Therapeutics COO Brendan Hannah buys $24,166 in company stock - Investing.com
QNCX Stock Earnings: Quince Therapeutics Reported Results for Q2 2024 - MSN
Quince Therapeutics: High-Potential Turnaround With Phase 3 Asset EryDex (NASDAQ:QNCX) - Seeking Alpha
Quince Therapeutics (NASDAQ:QNCX) Trading 1.5% Higher - Defense World
Quince reports data from Phase III Ataxia-Telangiectasia treatment trial - Clinical Trials Arena
Phase III data on Quince Therapeutics’ EryDex - The Pharma Letter
Quince Therapeutics reports progress in A-T treatment study - Investing.com
Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T) - StockTitan
Quince Therapeutics Inc: Buy, Hold, or Sell? Analysts Weigh In Amid Market Challenges - The InvestChronicle
Market Resilience: Quince Therapeutics Inc (QNCX) Finishes Weak at 0.58, Down -16.54 - The Dwinnex
Quince Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results - StockTitan
Quince Therapeutics (NASDAQ:QNCX) Trading Up 2.6% - Defense World
Reviewing Genenta Science (NASDAQ:GNTA) & Quince Therapeutics (NASDAQ:QNCX) - Defense World
Quince Therapeutics doses first subject in Ataxia-Telangiectasia trial - Clinical Trials Arena
Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia ... - Business Wire
Quince Therapeutics (NASDAQ:QNCX) versus Kymera Therapeutics (NASDAQ:KYMR) Critical Review - Defense World
Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-Telangiectasia - Yahoo Finance
Quince Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com Australia
Quince Therapeutics faces Nasdaq delisting over share price - Investing.com
Stock Surge: Quince Therapeutics Inc (QNCX) Closes at 0.68, Marking a -4.23 Increase/Decrease – DWinneX - The Dwinnex
Critical Review: Autolus Therapeutics (NASDAQ:AUTL) and Quince Therapeutics (NASDAQ:QNCX) - Defense World
Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results - br.ADVFN.com
O-I Glass, Inc. (NYSE:OI) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Comparing Ikena Oncology (NASDAQ:IKNA) & Quince Therapeutics (NASDAQ:QNCX) - Defense World
ChromaDex wins orphan designation for rare ataxia drug - Pharmaceutical Technology
FDA fast tracks Quince Therapeutics’ rare ataxia drug EryDex - Pharmaceutical Technology
Quince Therapeutics (NASDAQ:QNCX) Trading 5.7% Higher - Defense World
Ascend Wellness (OTC:AAWH) Shares Down 6.5% - Defense World
Short Interest in bioAffinity Technologies, Inc. (NASDAQ:BIAF) Rises By 7.1% - Defense World
Mandalay Resources (OTCMKTS:MNDJF) Stock Price Down 3% - Defense World
FDA fast tracks Quince Therapeutics' EryDex for A-T treatment - Investing.com South Africa
FDA fast tracks Quince Therapeutics' EryDex for A-T treatment By Investing.com - Investing.com
Quince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex System - StockTitan
Quince Therapeutics Inc Stock (QNCX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Quince Therapeutics Inc Stock (QNCX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Thye Dirk | CEO AND CHIEF MEDICAL OFFICER |
Aug 29 '24 |
Buy |
0.69 |
77,500 |
53,475 |
766,941 |
| Ryan Charles S. | PRESIDENT |
Aug 20 '24 |
Buy |
0.65 |
48,387 |
31,452 |
122,461 |
| Hannah Brendan | CHIEF BUSINESS OFFICER AND COO |
Aug 21 '24 |
Buy |
0.63 |
30,845 |
19,337 |
296,540 |
| Hannah Brendan | CHIEF BUSINESS OFFICER AND COO |
Aug 20 '24 |
Buy |
0.60 |
5,924 |
3,579 |
265,695 |
| Hannah Brendan | CHIEF BUSINESS OFFICER AND COO |
Aug 19 '24 |
Buy |
0.58 |
2,155 |
1,250 |
259,771 |
| Hannah Brendan | CHIEF BUSINESS OFFICER AND COO |
Jun 04 '24 |
Option Exercise |
0.55 |
56,061 |
30,834 |
257,616 |
| Thye Dirk | CHIEF EXECUTIVE OFFICER |
Jan 16 '24 |
Option Exercise |
0.79 |
240,530 |
190,791 |
689,441 |
| Lamond David | Director |
Dec 14 '23 |
Buy |
1.04 |
22,627 |
23,532 |
2,347,545 |
| Lamond David | Director |
Dec 12 '23 |
Buy |
1.02 |
22,327 |
22,774 |
2,302,291 |
| Lamond David | Director |
Dec 13 '23 |
Buy |
1.00 |
22,627 |
22,627 |
2,324,918 |
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):